Targeting the autophagic process is considered a promising therapeutic strategy in cancer since a great number of tumors, including melanoma, show high basal levels of protective autophagy that contributes to tumor progression and chemoresistance. Here, exploiting both in vitro and in vivo approaches, we identified N6-isopentenyladenosine (iPA), an end product of the mevalonate pathway, as a novel autophagy inhibitor with an interesting anti-melanoma activity. iPA, after being phosphorylated by adenosine kinase into 5′-iPA-monophosphate, induces autophagosome accumulation through AMPK activation, measured by increased fluorescent GFP-LC3 puncta and enhanced conversion into the lipidated autophagosome-associated LC3-II. However, at a later stage iPA blocks the autophagic flux monitored by p62 accumulation, Luciferase reporter-based assay for LC3 turnover in living cells and fluorescence of a tandem RFP-GFP-LC3 construct. Impaired autophagic flux is due to the block of autophagosome-lysosome fusion through the defective localization and function of Rab7, whose prenylation is inhibited by iPA, resulting in a net inhibition of autophagy completion that finally leads to melanoma apoptotic cell death. AMPK silencing prevents apoptosis upon iPA treatment, whereas basal autophagosome turnover is still inhibited due to unprenylated Rab7. These results strongly support the advantage of targeting autophagy for therapeutic gain in melanoma and provide the preclinical rational to further investigate the antitumor action of iPA, able to coordinately induce autophagosome accumulation and inhibit the autophagic flux, independently targeting AMPK and Rab7 prenylation. This property may be particularly useful for the selective killing of tumors, like melanoma, that frequently develop chemotherapy resistance due to protective autophagy activation. Cutaneous melanoma, although accounting for only the 5% of all cancer types, is the deadliest form of skin cancer with a very unfavorable prognosis when metastatic and with a median progression free-survival at the stage IV of less than 1 year.
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Here, exploiting both in vitro and in vivo approaches, we identified N6-isopentenyladenosine (iPA), an end product of the mevalonate pathway, as a novel autophagy inhibitor with an interesting anti-melanoma activity. iPA, after being phosphorylated by adenosine kinase into 5′-iPA-monophosphate, induces autophagosome accumulation through AMPK activation, measured by increased fluorescent GFP-LC3 puncta and enhanced conversion into the lipidated autophagosome-associated LC3-II. However, at a later stage iPA blocks the autophagic flux monitored by p62 accumulation, Luciferase reporter-based assay for LC3 turnover in living cells and fluorescence of a tandem RFP-GFP-LC3 construct. Impaired autophagic flux is due to the block of autophagosome-lysosome fusion through the defective localization and function of Rab7, whose prenylation is inhibited by iPA, resulting in a net inhibition of autophagy completion that finally leads to melanoma apoptotic cell death. AMPK silencing prevents apoptosis upon iPA treatment, whereas basal autophagosome turnover is still inhibited due to unprenylated Rab7. These results strongly support the advantage of targeting autophagy for therapeutic gain in melanoma and provide the preclinical rational to further investigate the antitumor action of iPA, able to coordinately induce autophagosome accumulation and inhibit the autophagic flux, independently targeting AMPK and Rab7 prenylation. This property may be particularly useful for the selective killing of tumors, like melanoma, that frequently develop chemotherapy resistance due to protective autophagy activation. Cutaneous melanoma, although accounting for only the 5% of all cancer types, is the deadliest form of skin cancer with a very unfavorable prognosis when metastatic and with a median progression free-survival at the stage IV of less than 1 year. 1 It is characterized by a high mutational rate of key oncogenes, which results in a wide range of molecular alterations responsible for its unresponsiveness to conventional chemotherapy and frequent resistance development. 2 Despite this, novel chemotherapy and immunotherapy protocols employing inhibitors of key proteins of the MAPK pathway such as BRAF, mutated in the 40-60% of melanomas, and the immune checkpoints PD-1 and CTLA-4, have undoubtedly improved the treatment of advanced melanoma. 3, 4 However, a substantial long-term survival benefit has not yet been reached and such novel therapies are also associated with the occurrence of resistance almost in all cases within a year and severe treatment-related adverse reactions that considerably narrow the spectrum of responsive patients. 5, 6 For these reasons and taking into account the growing incidence of melanoma worldwide in the last years, it is imperative to discover new targets and elaborate more effective and lasting therapeutic strategies.
Autophagy can be considered as a quality control mechanism crucial to preserve cellular homeostasis and viability under stressful conditions. 7 Its dysfunction may result in several human diseases, such as neurodegenerative disorders, cardiomyopathies and cancer. 8 Autophagy has a pivotal but complex role in cancer, preventing tumorigenesis in the early stages through the protection of cells from genetic instability, metabolic stress and chronic inflammation. Conversely, it promotes cancer cell survival in established or advanced tumors, providing the substrates to sustain tumor metabolism and growth and protect from drug-induced stress. 9, 10 A great number of tumors, including melanoma, show high basal levels of autophagy linked to tumor aggressiveness, weak response to chemotherapy, poor outcome and reduced survival. 11 Therefore, a deliberate autophagy inhibition strategy, in combination with classic chemotherapy and immunotherapy protocols, could be useful to improve the therapeutic efficacy and contrast chemoresistance.
N6-isopentenyladenosine (iPA) is a product of the mevalonate pathway, constituted by an adenosine moiety modified at the nitrogen in the position 6 of the purine base with an isopentenyl chain derived from the mevalonate precursor dimethylallyl pyrophosphate, which is in equilibrium with its isomer, isopentenyl pyrophosphate. [12] [13] [14] [15] [16] The exact role of free iPA inside mammalian cells has not been fully disclosed. 17 The interest in the study of the biological properties of this compound has been strengthened by several experimental observations regarding a promising antitumor efficacy in preclinical models of different malignant tumors exerted through multiple mechanisms of action including the inhibition of proliferation, the block of cell cycle and the induction of apoptosis. [18] [19] [20] [21] [22] [23] Among the possible iPA biochemical targets proposed, the inhibition of farnesyl diphosphate synthase (FDPS) and hence of protein prenylation is the most supported. 18, 24 More recently, we reported that iPA is monophosphorylated into 5′-iPA-monophosphate (iPAMP) by the adenosine kinase (ADK) and in this form it directly activates AMP-activated protein kinase (AMPK) in endothelial cells, thus inhibiting the angiogenic process both in vitro and in vivo. 25 AMPK, a sensor of energy status that regulates cellular energy homeostasis, is activated by stimuli that augment the AMP/ATP ratio or by AMP mimetics, resulting in the inhibition of protein synthesis and in the activation of autophagy. 26 Since autophagy is a mechanism that could be successfully targeted for therapeutic gain in melanoma patients and given the antitumor properties of iPA and its ability to target AMPK, in the present study we investigated for the first time the involvement of the autophagic process in the antitumor action of iPA in both in vitro and in vivo models of melanoma.
Results
iPA inhibits melanoma cell proliferation and colony formation inducing G1-phase stasis. At first, the direct effect of iPA on A375 melanoma cells viability was investigated. iPA inhibited time-and dose-dependently melanoma cell proliferation in the low micromolar range (Figure 1a , black bars). The time-dependency was lost at longer time points. In order to investigate the mechanism through which iPA exerted its inhibitory effects and to confirm the phosphorylation in position 5′-by ADK as pivotal for iPA action, 25 melanoma cells were pre-treated with an ADKspecific inhibitor, 5-Itu (30 nM, 30 min). The pre-treatment with 5-Itu (Figure 1a , gray bars) prevented the effects of iPA on melanoma cell proliferation at all the concentrations and time points, confirming that the active metabolite is actually N6-isopentenyladenosine 5'-monophosphate (iPAMP) and therefore that the phosphorylation of iPA in C5 by ADK results to be crucial also to the antitumor activity of iPA. Also prolonged exposure to iPA inhibited colony formation in a concentration-related manner, reducing the number and dimension of colonies. Once again, the pre-treatment with 5-Itu completely reverted the inhibitory effect of iPA on longterm colony formation (Figure 1b) . To analyze the precise nature of the antiproliferative action of iPA, melanoma cell cycle distribution was evaluated. As shown by quantitative analysis, iPA blocked proliferation of melanoma cells in G1 phase already after 24 h of treatment at the highest concentration tested and this effect was increased after 48 h of treatment (Figure 1c) . After 72 h of treatment the G1-phase stasis was no more relevant. These data demonstrate that iPA displays an inhibitory activity in the low micromolar concentration range on both short-and long-term melanoma cell growth.
iPA induces autophagosome accumulation through AMPK activation and inhibition of the mTOR pathway. We previously demonstrated that iPA was able to activate the AMPK pathway in endothelial cells, thus inhibiting the angiogenic process. 25 To investigate whether iPA was able to activate the AMPK pathway also in melanoma cells, phosphorylation at Thr-172 of the AMPK-α catalytic subunit was evaluated as a read-out of its activity. A dose-dependent induction of AMPK phosphorylation was detected at 24 h, whereas the total levels of AMPK protein were not affected (Figure 2a ). We next analyzed the effect of iPA on mTOR, a downstream effector of AMPK, showing that iPA caused a dose-dependent inhibition of mTOR phosphorylation, thus inhibiting its function. Further, we examined one of the main mTOR targets, p70S6K, whose phosphorylation at Ser-371 directly reflects mTOR activity. We observed, also in this case, a dose-dependent inhibition of phosphorylation, particularly evident at the 10 μM dose (Figure 2a ). Since it is wellestablished that the AMPK pathway, also through mTOR downregulation, is a key regulator of cellular responses including autophagy, we next investigated if iPA might affect the autophagic process. A375 cells, as several melanoma cell lines and primary melanoma lesions, are characterized by basal levels of autophagy activation. 9 During autophagy, the marker LC3 (microtubule-associated protein-1 light chain-3) translocates from the cytosol into the autophagosomes, thus redistributing from a diffuse cytoplasmic location to discrete puncta. As shown in Figure 2b a redistribution of GFP-LC3 from a diffuse cytoplasmic location to a punctate fluorescence occurred upon iPA treatment. The number of fluorescent puncta and also the number of total cells with punctate GFP-LC3 fluorescence increased in a dosedependent manner in treated cells with respect to the control. LC3 translocation into autophagosomes was further confirmed biochemically through western blot, examining the conversion of the non-lipidated LC3-I into the lipidated autophagosome-associated form LC3-II. We found that iPA enhanced the accumulation of LC3-II in a time-and dosedependent manner (Figure 2c ). All together these data suggest that iPA treatment results in autophagosome accumulation in melanoma cells.
Autophagosome accumulation is due to autophagic flux inhibition by iPA. It has been extensively demonstrated that an induction of LC3-II expression and increased numbers of autophagosomes can be due to the activation of autophagy that leads to an increased autophagosome production but also to the inhibition of the autophagic process at a later step, resulting in a reduction of autophagosome turnover. In order to discern among these two different possibilities, the next step was to measure the autophagic flux. At first, we checked through immunoblot the protein levels of p62/SQSTM1, a sensitive autophagy substrate implicated in autophagic cargo recognition, that is degraded in the later stages of autophagy, reflecting autophagosome turnover. Consistent with this notion, we observed a time-and dose-dependent accumulation of p62 upon iPA treatment, that is suggestive of autophagic flux inhibition (Figure 2c ). This phenomenon was further confirmed by confocal microscopy analysis. iPA treatment led to a dose-dependent accumulation of p62 and GFP-LC3 puncta in big spots, mainly concentrated near the nucleus, that showed extensive co-localization, suggesting that iPA inhibited autophagic flux at a late stage (Figure 3a) .
In order to clarify the reason of iPA-induced accumulation of LC3-II and GFP-LC3 positive puncta, we measured autophagic flow by employing a Renilla luciferase (RLuc) reporterbased assay for LC3 turnover in living cells. 27 This assay allows to compare the rate of LC3 degradation during the autophagic process in melanoma cells expressing RLuc fused to either wild-type LC3 or mutant LC3 (G120A) that is unable to undergo to cleavage and lipidation-dependent changes. Autophagic flux was not induced by iPA since there was not a lipidation-dependent gradual loss of RLuc-LC3, as observed also with HCQ treatment, a known inhibitor of autophagy (RLuc-LC3
WT / G120 = 1.12) (Figure 3b ).
Another powerful way to monitor the autophagic flux, evaluating at the same time the fusion of autophagosomes with lysosomes, employs the measurement of the fluorescence change of a tandem RFP-GFP-LC3 construct, which allows to distinguish autophagosomes from autolysosomes. Indeed, upon the fusion of autophagic vesicles with lysosomes the GFP fluorescence is quenched by the acidic environment, WT and RLuc-LC3 G120A transfected cells were cultured for 48 h and then treated in parallel with increased concentrations of iPA. Luciferase activity was detected as described in Materials and Methods using the luciferase substrate coelenterazine (EnduRen), optimized for use in living cells, allowing a live cell kinetic analysis of autophagic flux in our assay system. Data represent the mean ± S.D. of three independent experiments performed in triplicates. (c) A375 cells transiently expressing RFP-GFP-LC3 construct were treated with increasing concentrations of iPA (2.5, 5, 10 μM) for 48 h, followed by staining with anti-LAMP-1 (blue). Representative pictures are shown. Original magnification: × 63. Scale bars: 25 μM whereas the RFP signal is not affected. 28 iPA treatment led to a dose-dependent increase also of red fluorescence puncta, indicating once again autophagosomes accumulation. However, the treatment resulted in the increasing of yellow puncta (co-localization of GFP and RFP fluorescence in the absence of GFP quenching), and decreasing of red-only puncta and purple puncta (co-localization of RFP-LC3 and LAMP-1, lysosome marker), suggesting an impairment of autophagosome-lysosome fusion ( Figure 3c ).
All together these data indicate that the accumulation of autophagosomes induced by iPA is due to an impairment of the autophagic flux due to distal autophagy blockade.
iPA impairs autophagic flux inhibiting autophagosomelysosome fusion through unprenylated Rab7. A possible reason for the impaired autophagic flux induced by iPA could be the inhibition of fusion of autophagosomes with late endosomes or lysosomes. Since autophagosome-lysosome fusion has been reported to be dependent on the acidic environment, lysosome functionality was evaluated. 29 To this end, two specific pH probes, LysoTracker Red and acridine orange, were employed. iPA induced a dose-and timedependent accumulation of acidic vesicles as testified by an increased fluorescence intensity of the two probes (Figures 4a and b) . Lysosomal functionality, monitored by measuring cathepsin B activity through an enzymatic assay, was not deteriorated by iPA treatment that, on the contrary, induced cathepsin B activity in a dose-dependent manner ( Figure 4c ). Therefore, the inhibition of autophagosomelysosome fusion is not linked to an impaired lysosomal acidification or degradative function. Next, the effects on autophagosome maturation were assessed by measuring the co-localization efficiency of GFP-LC3 labeled autophagosomes with LysoTracker Red-stained lysosomes. As detected, the fusion efficiency of GFP-LC3 with LysoTracker Red lysosomes was inhibited by iPA, differently from HCQ that is known to inhibit autophagy by raising lysosomal pH (Figure 4d ), confirming the observed inhibition of RFP-LC3 and LAMP-1 co-localization (Figure 3c ). The process of how autophagosomes are guided to fuse with lysosomes is one of the crucial steps in autophagy. The completion of autophagosome maturation and the fusion with lysosomes requires the small GTPase Rab7, a prenylated protein that in the active form (Rab-GTP) associates to the membrane. 30 We already disclosed that iPA inhibits FDPS activity and consequently it affects protein prenylation. 18, 24 iPA treatment inhibited protein prenylation inducing accumulation of unprenylated HDJ-2 and Rap1A (U-Rap1A), as a measure of protein prenylation inhibition (Figure 4e ). The effect was specific on prenylation, since the total levels of Rap1A were not affected. More interestingly, as regard to Rab7 prenylation we observed a dose-dependent accumulation of unprenylated Rab7 (U) with respect to the prenylated form (P) upon iPA treatment, detected by a change in electrophoretic mobility by EMSA (Figure 4e ). To further understand how iPA blocks the autophagic flux, the intracellular distribution of Rab7 was evaluated. Both GFP-LC3 and Rab7 showed punctate staining in the cytoplasm. Co-localization of both GFP-LC3 and Rab7 and GFP-LC3, Rab7 and Lysotracker, was inhibited by iPA. Upon iPA treatment, unprenylated Rab7 was unable to associate with the membrane and maintained a cytoplasmic punctate localization. Cells treated with HCQ, which does not affect prenylation, showed a different pattern of Rab7 localization mainly concentrated to the membrane in bigger spots and surrounding GFP-LC3 larger aggregates accumulating near to the perinuclear region ( Figure 4d ). All together our data argue for the inhibition of autophagosomelysosome fusion by iPA through unprenylated Rab7.
Inhibition of autophagy leads to apoptotic cell death. To further examine whether iPA-mediated autophagic flux inhibition eventually affected melanoma cell survival, apoptotic cell death was analyzed. iPA exerted a dose-and timedependent increase in the percentage of apoptotic cells, whereas there were no signs of necrotic cell death (Figure 5a ). In order to confirm that phosphorylation into iPAMP by ADK was crucial for iPA pro-apoptotic action and also to indirectly disclose the involvement of AMPK activation in such effects, melanoma cells were pre-treated with 5-Itu that prevented the pro-apoptotic action of iPA (Figure 5b ). The activation of the intrinsic apoptosis pathway was monitored by the analysis of the caspase cascade. Caspase-9 activation, started from 24 h upon iPA treatment, followed by caspase-3 activation at 48 h and resulted in DNA repair enzyme poly(ADP-ribose) polymerase (PARP) cleavage, that finally leads to apoptotic cell death. The activation of such pro-apoptotic proteins by iPA was prevented by 5-Itu (Figure 5c ). Following 5-Itu pre-treatment iPA was not more iPA effects on autophagosome accumulation and apoptosis induction are dependent on AMPK activation. On the basis of the previous findings, to address whether AMPK activation plays an essential role in iPA inhibition of the autophagic flux and subsequent activation of apoptotic cell death, we determined its effects on both autophagy and apoptosis following AMPK α1 catalytic subunit knockdown by small interfering RNA (siRNA) (Figure 6 ) or pharmacological inhibition by Compound C (Supplementary Figure 1a) . AMPK silencing was confirmed by immunoblot of total AMPK expression, which showed at least 50% of inhibition (Figure 6b ). Genetic inhibition of AMPK prevented iPAinduced apoptosis (Figure 6a ) evidenced also by cathepsin B activation, implicated in apoptosis (Figure 6b ) and by measurement of caspase-3 and PARP cleavage. Further, AMPK siRNA counteracted iPA-induced accumulation of lipidated LC3-II and GFP-LC3 fluorescent puncta that therefore is AMPK-dependent (Figures 6c and d) . The autophagic flux completion, evaluated by p62 levels that remained elevated with AMPK siRNA, was still inhibited by iPA treatment and so independent from AMPK ( Figure 6c ). As a reason of this, Rab7 distribution, following AMPK silencing and upon iPA treatment, maintained a diffuse punctate cytoplasmic localization typical of the unprenylated inactive form (Figure 6d ). Therefore, AMPK signaling pathway is not linked to the inhibition of Rab7 prenylation by iPA. These observations support the evidence that activation of AMPK by iPA is necessary for stimulation of both autophagosomes accumulation and apoptosis but not for the inhibition of Rab7 prenylation and hence for the block of fusion of autophagosomes with lysosomes and the completion of the autophagic process.
iPA inhibits autophagic flux exerting antitumor efficacy in vivo. Finally, in order to confirm a potential antitumor effect of iPA in vivo, melanoma xenografts were generated by subcutaneous inoculation of A375 cells in athymic mice. A rapid and dramatic tumor growth was observed throughout the course of the experiment in the control group, whereas tumors from iPA-treated mice were consistently and significantly smaller ( Figure 7a ). As anticipated, treatment with iPA significantly enhanced AMPK phosphorylation and activation, reducing mTOR phosphorylation, as already observed in vitro (Figure 7b) . A trend of p62 accumulation was also observed, even if statistical significance was not reached due to high basal p62 levels in one of the control mice (#4). Moreover, we observed an accumulation of unprenylated Rab7 (U) with respect to the prenylated form (P) (Figure 7b ). Overall, these data clearly confirm in vivo the interesting anti-melanoma activity of iPA that acts through AMPK pathway stimulation and inhibition of Rab7 prenylation, resulting in the block of autophagic flux.
Discussion
The discovery of new effective compounds that may be used with success in melanoma treatment is a fundamental challenge, in particular to treat those tumors that are resistant or non-responsive to the available therapies. To this aim, exploiting both in vitro and in vivo approaches, in this study we demonstrated for the first time the interesting anti-melanoma activity of the isoprenoid derivative iPA. Prior studies have already reported the antitumor action of iPA in different tumor types. [18] [19] [20] [21] [22] [23] 31 In addition to a direct antitumor activity, iPA displays pleiotropic properties able to interfere with tumor growth at different levels, being also an angiogenesis inhibitor and an immunomodulator that selectively activates natural killer cells. 25, 32, 33 However, the effect of iPA on the autophagic process has never been previously recognized. In the present study we have identified and characterized iPA as a novel autophagy inhibitor that causes a substantial accumulation of autophagosomes followed by inhibition of the autophagic flux and final induction of melanoma cell death both in vitro and in vivo. Targeting the autophagic process is currently considered a promising therapeutic strategy in cancer and its monitoring has been also proposed to have a prognostic relevance. 34 Indeed, while autophagy suppresses tumorigenesis at early stages, in a great numbers of advanced tumors, including melanoma, it promotes progression being also responsible of chemo-and radio-resistance. 35, 36 A high autophagic index in melanoma correlates to a worse prognosis, with higher invasiveness, lympho nodes metastases, poor response to chemotherapy and reduced survival.
11,37 For these reasons, autophagy inhibition could be a successful strategy for therapeutic gain in melanoma patients. Most well-established autophagy inhibitors evaluated in the clinic in combination with chemotherapeutic drugs are HCQ derivatives that act increasing lysosome basicity causing its dysfunction. 38, 39 Recent screening of natural compounds led to the discovery of elaiophylin, a macrolide antibiotic with a N6-isopentenyladenosine impairs autophagic flux R Ranieri et al chemical structure distinct from HCQ, able to block autophagic flux by impairment of lysosomal cathepsin activity and exert antitumor activity in ovarian cancer. 40 Here, we reported that also iPA is a late-stage inhibitor of autophagy, preventing the autophagosome-lysosome fusion through unprenylated Rab7, thus blocking the autophagic flux without affecting lysosome acidity and functionality. A proper autophagic flux is indeed determined by the equilibrium between autophagosome formation and clearance by lysosomes. Rab7 is a small GTP-binding protein that peripherally associates with membranes through a geranylgeranyl lipid tail derived from the isoprenoid pathway. Its GTP-bound form is generally thought to mediate its functions through specific interactions with effector proteins, whereas the inactive form Rab-GDP resides in the cytosol. 30 Active Rab7 is required for the maturation of late autophagosomes and fusion with lysosomes. Overexpression of a dominant-negative Rab7 mutant in mammalian cells leads to the accumulation of large autophagosomes, caused by autophagic flux interruption. 41 Moreover, inhibition of Rab geranylgeranyl transferase (GGTase II) and hence of Rab prenylation results in a net block of autophagy. 42 Consistent with these observations, our study revealed that there is a significant increase not only in the number but also in the size of autophagosomes in cells treated with iPA, suggesting that autophagosome accumulation is caused by iPA-induced defects in the late autophagosome-lysosome fusion step of autophagy due to a defective localization and function of Rab7 caused by its defective prenylation. Indeed, we already reported that iPA inhibits the activity of FDPS and consequently it may affect prenylation of target proteins like small GTPases. 18, 24 We confirmed that iPA treatment dosedependently inhibits protein prenylation preventing a proper localization and function of Rab7 that shows a punctate cytoplasmic distribution and does not colocalize with both autophagosome and lysosome markers (LC3 and LysoTracker). It is possible however that other members of the Rab family, which may function in parallel or synergistically with Rab7 in autophagosome maturation, may be also involved in iPA action. Indeed, both statins and Rab11 knockdown have been reported to inhibit autophagic flux at late stages. 43 Hence, iPA belongs to a novel class of autophagy modulators able to simultaneously induce the autophagic process upstream and block the autophagic flux downstream, which could be useful as single agents in cancer therapy or in combination with classic chemotherapy with synergistic effects on cell death induction. 44 The simultaneous activation and inhibition of autophagy has been reported as an interesting approach for chemotherapy sensitization, especially in those tumors with high basal levels of cytoprotective autophagy, as melanoma. 45 We observed that iPA induces autophagosome accumulation through AMPK activation both in vitro and in vivo. Indeed, as we already reported in endothelial cells, iPA behaves as an AMP mimetic, being phosphorylated by ADK into its 5′monophosphorylated derivative iPAMP, that in turn activates AMPK. 25, 46 AMPK is a key mediator of autophagy, being an energetic sensor that activates autophagy in response to cellular stresses like nutrient deprivation, hypoxia, chemotherapy or targeted therapies, by inhibiting mTOR signaling pathway both in cytoprotective and in cytotoxic autophagy. 47 Strategies aimed to inhibit in a coordinated manner both mTOR pathway and autophagy showed a promising antitumor effect in melanoma. 48 Interestingly, we observed that the dual effect of iPA on autophagosome accumulation and autophagic flux inhibition relies on different and independent mechanisms, that are respectively AMPK activation and inhibition of Rab7 prenylation (Figure 8) . Indeed, even when AMPK is selectively silenced in melanoma cells through siRNA, Rab7 prenylation is inhibited upon iPA treatment and hence it remains into the cytoplasm in the inactive form. This is confirmed by the finding that p62 still accumulates when AMPK is silenced, because of the inhibition of basal autophagosome turnover. The apoptotic process, which is activated by iPA following autophagy inhibition, is prevented by AMPK silencing or 5-Itu pretreatment, which acts upstream blocking iPA phosphorylation by ADK, and so is AMPK-dependent. These observations are fundamental to demonstrate the intimate connection among autophagy and apoptosis in the mechanism of action of iPA. Its ability to activate AMPK induces autophagosomes accumulation that are unable to be degraded because of its inhibition of autophagosome clearance, thus becoming detrimental for the cell that induces the apoptotic cell death program, through the intrinsic cascade, confirmed by caspase-9 activation followed by caspase-3 and PARP cleavage. Moreover, iPA does not impair lysosomal functionality, thus allowing the involvement of lysosome proteases in iPA-induced cell death. Autophagy is induced by chemo-and radiotherapy to protect cells from apoptosis and inhibition of autophagy enhances the antitumor effect inducing the apoptotic process. On the other hand, several antitumor treatments have been reported to induce an autophagic cell death independently from apoptosis, especially in those tumors that are resistant to apoptosis. 49 The combinatorial strategy with cytotoxic drugs is functional to impede or reverse chemotherapy resistance, overcoming autophagy-mediated cytoprotection in cancer therapy Interestingly, compounds like iPA able to induce autophagy simultaneously being cytotoxic through the impairment of autophagosomes final degradation could be also useful as standalone agents in therapy.
The results of our study strongly support the advantage of therapeutic targeting of autophagy in melanoma and provide the preclinical rational to further investigate the antitumor action of iPA, a novel compound that thanks to its peculiar structure is able to induce autophagosome accumulation inhibiting at the same time the autophagic flux. This property may be particularly useful for the selective killing of those tumors, like melanoma, that frequently develop chemotherapy resistance due to protective autophagy activation. Cell cycle analysis. Melanoma cells were plated in 100-mm dishes. To synchronize cells at the G1/S interface, they were serum starved in medium with 0.5% serum for 18 h. Cells pre-treated or not with 5-Itu (30 nM, 30 min) were treated with iPA. After 24 h, the cells were collected, fixed in 70% ethanol and kept at − 20°C overnight. Propidium iodide (PI; 50 μg/ml) in PBS containing 100 U/ml DNase-free RNase was added to the cells for 15 min at room temperature. The cells were acquired by a FACSCalibur flow cytometer (BD Biosciences, San Jose, CA, USA). The analysis was performed with ModFit LT v3.2 (Verity Software House, Inc., Topsham, ME, USA); 10 000 events, corrected for debris and aggregate populations, were collected.
Apoptosis analysis. Briefly, cells grown in six-well culture plates were harvested using trypsin and washed in PBS. Then, the cells were resuspended in Annexin V binding buffer (10 mM HEPES/NaOH, pH 7.4, 140 mM NaCl, 2.5 mM CaCl 2 ) and stained with Annexin V-FITC (BMS147FI; eBioscience, San Diego, CA, USA) for 20 min and after with PI at room temperature for additional 15 min in the dark. The cells were acquired by flow cytometer (BD Biosciences) within 1 h after staining. At least 30 000 events were collected, and the data were analyzed by CellQuest Pro software (BD Biosciences).
Flow cytometric analysis of autophagy. Melanoma cells were grown in six-well culture plates and incubated with drugs, iPA, 5-Itu and chloroquine as indicated in the text. After, cells were washed with PBS, harvested with trypsin and washed in PBS. LysoTracker Red DND-99 (excitation/emission, 577/590 nm) was added to melanoma cells at a final concentration of 50 nM for 30 min at 37°C. The quantification of acidic vesicular organelles (AVO), as a marker of autophagy, was detected by staining melanoma cells with lysosomotropic agent acridine orange (2 μg/ml) for 15 min at 37°C. The cells were acquired by a flow cytometer. At least 30 000 events were collected and the data were analyzed by FlowJo software (FlowJo LLC, Ashland, OR, USA) or by Cell-Quest Pro software (BD Biosciences).
Western blot. After treatment, A375 cells were washed with PBS, detached using trypsin and collected with ice-cold RIPA Buffer (50 mM Tris-HCl, 150 mM NaCl, 0.5% Triton X-100, 0.5% deoxycholic acid, 10 mg/ml leupeptin, 2 mM phenylmethylsulfonyl fluoride and 10 mg/ml aprotinin). Cell debris were removed by centrifugation (14 500 g for 20 min at 4°C) and then the protein concentration was determined by Biorad Protein Assay (Biorad, Richmond, CA, USA). About 15 to 30 μg of proteins were resuspended in sample buffer, loaded onto SDSpolyacrylamide gels under reducing conditions and then transferred to nitrocellulose membranes. The membranes were blocked with 5% non-fat dry milk (Biorad) and incubated with the specific antibodies overnight at 4°C. Immunodetection of specific proteins was carried out with horseradish peroxidase-conjugated secondary antibody for 1 h at room temperature. The membranes were stained by using the enhanced chemiluminescence system (Amersham Biosciences, Amersham, UK). If necessary, the membranes were stripped and reprobed with another antibody. Immunoreactive bands were quantified using ImageJ software (US National Institutes of Health, Bethesda, MD, USA). The intensity of the staining of α-tubulin (using α-tubulin monoclonal antibody; Sigma-Aldrich) and the total amount of each of the studied proteins were used as loading controls for data normalization.
Cathepsin assay. The activity of lysosomal cathepsin proteases was determined using the Cathepsin B Activity Assay kit (BioVision, Milpitas, CA, USA). Briefly, 50 μg of cell lysates were resuspended in Cathepsin B Cell Lysis Buffer and then the Cathepsin B Reaction Buffer was added to each sample following the manufacturer's protocol. The activity of Cathepsin B was expressed as fold-increase in relative fluorescence units (RFU) compared to the level of negative control sample.
Transfections. For the reporter assay in living cells, melanoma cells were transient transfected with 5 μg/μl of RLuc-LC3 wt and RLuc-LC3 G120A in 1 × 10 6 cells using Nucleofector (Lonza, Basel, Switzerland) according to the manufacturer's instructions.
Transient transfection of siRNA was performed with RNAiMAX (Invitrogen, Thermo Fisher Scientific, Waltham, MA, USA) according to the manufacturer's instructions using 200 nM of siRNA for AMPK.
RLuc reporter assay for autophagic flux measurement. RLuc reporter assays for autophagic flux were performed in live cells as described. 27 Melanoma cells were transfected with RLuc-LC3 wt and RLuc-LC3 G120A and then were plated in white 96-well plates. The following day, medium was replaced with fresh culture medium and the cells were treated with different concentrations of iPA. After 24 h, 60 nM of Enduren substrate (Promega, Madison, WI, USA; E6481) dissolved in medium was added to the cells. RLucLC3 activity was assessed in kinetic measurement using the EnSpire Multilabel Plate Reader (PerkinElmer, Waltham, MA, USA). The luminescence measurement was performed at indicated intervals of 2, 4 and 12 h. Finally the luminescence was determined as the ratio of RLucLC3 wt and RLucLC3
mut
. These values were normalized to time point zero for a given treatment. The mRFP-EGFP-LC3 construct created by T Yoshimori was used to analyze the autophagic flux through confocal images. Cells were transfected with ptfLC3-expressing plasmid using Lipofectamine 3000 (Invitrogen) according to the manufacturer's instructions and then treated with indicated concentration of iPA for 48 h. After, cells were submitted to confocal procedure.
Confocal microscopy. Melanoma cells were grown on glass coverslips in 12-well plates. After 24 h cell medium was replaced and cells were treated for 48 h with iPA at different concentrations (1-10 μM). Then, cells were washed with PBS and fixed with 4% parafolmaldehyde for 15 min; cells were washed in PBS and blocked with blocking solution (0,1% Triton, 1% BSA, 0.02% sodium azide, 50 mM ammonium chloride) for 20 min at room temperature in the dark. Afterwards cells were incubated with anti-p62 (Abcam #109012), Rab7 (Cell Signaling Technology; 9367) and anti-LAMP-1(Abcam #24170) at a final concentration of 1 μg/ml at room temperature for 1 h. Immunofluorescence staining was obtained by incubating for 90 min with Alexa Fluor 488 donkey anti-rabbit IgG (A31573) and Alexa Fluor 647 donkey anti-rabbit IgG (A21206) secondary antibody at a final concentration of 4 μg/ ml, respectively (Invitrogen). To evaluate lysosomal functionality cells were labeled with LysoTracker Red 75 nM for 2 h at 37°C and then fixed. The nuclei were counterstained with DAPI (1:2000) and slides were mounted using VectaMount solution (AQ Vector Laboratories, Burlingame, CA, USA). Cells were examined under a Leica confocal microscope (Leica Microsystems, Milan, Italy) and then analyzed through ImageJ software as previously described. 50 In vivo studies Animals: Twenty female SCID mice (SHO, 6-8 weeks old) were obtained from Charles River Laboratories Italia (Lecco, Italy). Animals were maintained under clean room conditions in sterile filter top cages with Alpha-Dri bedding and housed on high-efficiency particulate air-filtered ventilated racks. Animals received sterile rodent chow and water ad libitum. Mice were randomized among and regrouped such that tumor volumes of all groups of mice were in the same range and began to receive treatment. iPA was administered every day by peritumoral injection for 3 weeks at 5 or 10 mg/kg/dose in 150 μl of PBS. Animals in the corresponding control group received PBS (150 μl) N6-isopentenyladenosine impairs autophagic flux R Ranieri et al peritumoral injected on the same schedule as iPA. Mice were daily monitored for clinical signs and mortality. Body weight recordings were carried out bi-or threeweekly. Progress of tumors was daily determined by external two-dimensional caliper measurements, and tumor volumes were calculated using a standard hemiellipsoid formula: (length (mm) × width (mm) 2 )/2. Tumor volumes were analyzed using one-way ANOVA. At the end of study, mice were humanely killed and tumors were resected and frozen immediately or fixed in 10% formalin for further analysis.
For western blot analysis, frozen tumor pieces were disrupted for protein extraction by gentle homogenization (Potter-Elvehjem Pestle) in cold RIPA buffer. After removal of cell debris by centrifugation (14 500 g for 20 min at 4°C), the protein amounts were estimated.
Statistical analysis. Statistical computations were performed using the GraphPad Prism 6.0 software (La Jolla, CA, USA). Data obtained from multiple experiments were calculated as mean ± S.D. and analyzed for statistical significance by using the two-tailed Student's t-test, for independent groups, or ANOVA followed by Tukey correction for multiple comparisons. P-values less than 0.05 were considered statistically significant.
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